Iclusig Oral Tablet 15Mg Drug Medication Dosage Information
show timeout overlay link

Your Session Is About to Expire

This online session is about to expire due to inactivity. Click Continue to return to page.

  • myWeekly Ad

Iclusig: Oral tablet (15mg)

Also see:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics

Visit Drug Summary Page
Drug Image file DrugItem_16038.JPG
Iclusig 15mg Tablet
ARIAD Pharmaceuticals, Inc.
Pill Identification: A5 

What is this Medicine?

PONATINIB (poe NA ti nib) is a chemotherapy drug. It targets specific proteins within cancer cells and stops the cancer cell from growing. This medicine is used to treat chronic myelogenous leukemia and certain types of acute lymphoblastic leukemia.

In-Depth Information

Iclusig 15mg Tablet

NDC: 761890535
  • Prescription Required
  • Not a Controlled Drug
    (CSA Schedule)
  • FDA Approved




FDA approved for the following conditions:
Acute Lymphocytic Leukemia (ALL), Chronic Myelogenous Leukemia (CML)

Storage Information
Store between 68 to 77 degrees F, excursions permitted 59 to 86 degrees F
Iclusig 15mg Tablet
Drug Image file DrugItem_16038.JPG
ARIAD Pharmaceuticals, Inc.
Pill Identification: A5 
Shape: round
Color: white

Reported Side Effects for Iclusig 15mg Tablet

Electrolyte Imbalance Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Muscle Pain Incidence:
<1.0%*
Severity: SEVERE
Onset: EARLY
Mouth Sores Incidence:
<3.0%*
Severity: SEVERE
Onset: DELAYED
Melena Incidence:
<2.0%*
Severity: MODERATE
Onset: DELAYED
Mouth Ulcers Incidence:
<3.0%*
Severity: SEVERE
Onset: DELAYED
Dry Skin Incidence:
<2.0%*
Severity: SEVERE
Onset: DELAYED
High Amylase Levels Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Liver Failure Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Hole In Intestines Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Vomiting Of Blood Incidence:
<2.0%*
Severity: SEVERE
Onset: DELAYED
High Sodium Levels Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Infection Incidence:
<22.0%*
Severity: SEVERE
Onset: DELAYED
Fluid Retention Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Nerve Pain Incidence:
<2.0%*
Severity: SEVERE
Onset: DELAYED
Chills Incidence:
<2.0%*
Severity: SEVERE
Onset: RAPID
Tumor Lysis Syndrome (TLS) Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Vomiting Incidence:
<2.0%*
Severity: SEVERE
Onset: EARLY
Back Pain Incidence:
<2.0%*
Severity: SEVERE
Onset: DELAYED
Upset Stomach Incidence:
<2.0%*
Severity: SEVERE
Onset: EARLY
Decreased Appetite Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Joint Pain Incidence:
<2.0%*
Severity: SEVERE
Onset: DELAYED
Extra Abdominal Fluid Incidence:
<1.0%*
Severity: MODERATE
Onset: DELAYED
Bone Pain Incidence:
<3.0%*
Severity: SEVERE
Onset: DELAYED
Slow Heart Beat Incidence:
<1.0%*
Severity: SEVERE
Onset: RAPID
Swelling Of The Brain Incidence:
<1.0%*
Severity: SEVERE
Onset: EARLY
Constipation Incidence:
<3.0%*
Severity: SEVERE
Onset: DELAYED
Stomach Abnormality Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Loose Stools Incidence:
<3.0%*
Severity: SEVERE
Onset: EARLY
Shortness Of Breath Incidence:
<7.0%*
Severity: SEVERE
Onset: EARLY
Fever Incidence:
<5.0%*
Severity: SEVERE
Onset: EARLY
Headache Incidence:
<3.0%*
Severity: SEVERE
Onset: EARLY
High Triglycerides Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Very Rapid Heart Rate Incidence:
0.2%*
Severity: SEVERE
Onset: EARLY
Heart Block Incidence:
0.2%*
Severity: SEVERE
Onset: EARLY
Irritated Blood Vessels Incidence:
0.7%*
Severity: MODERATE
Onset: RAPID
Rapid Heart Rate Incidence:
0.9%*
Severity: MODERATE
Onset: EARLY
Irregular Heart Rate Incidence:
0.9%*
Severity: SEVERE
Onset: EARLY
Low Calcium Levels Incidence:
1.0%*
Severity: SEVERE
Onset: DELAYED
High Bilirubin Level Incidence:
1.0%*
Severity: SEVERE
Onset: DELAYED
Blood Clot In Lung Incidence:
1.3%*
Severity: SEVERE
Onset: DELAYED
Intestinal Bleeding Incidence:
2.0%*
Severity: SEVERE
Onset: DELAYED
High Potassium Level Incidence:
2.0%*
Severity: SEVERE
Onset: DELAYED
Low Potassium Levels Incidence:
2.0%*
Severity: SEVERE
Onset: DELAYED
High Blood Pressure Incidence:
2.0%*
Severity: SEVERE
Onset: EARLY
Bleeding In The Brain Incidence:
2.0%*
Severity: SEVERE
Onset: DELAYED
Blood Clot In Eye Incidence:
3.0%*
Severity: SEVERE
Onset: DELAYED
Weakness Incidence:
3.0-6.0%*
Severity: SEVERE
Onset: DELAYED
Bleeding In Eye Incidence:
3.0%*
Severity: SEVERE
Onset: DELAYED
Sore Throat Incidence:
3.0-12.0%*
Severity: MILD
Onset: DELAYED
Lightheadedness Incidence:
3.0-11.0%*
Severity: MILD
Onset: EARLY
Fluid Retention Incidence:
3.0%*
Severity: SEVERE
Onset: DELAYED
Macular Edema Incidence:
3.0%*
Severity: SEVERE
Onset: DELAYED
Fluid Around The Heart Incidence:
3.0%*
Severity: SEVERE
Onset: DELAYED
Tired Incidence:
3.0-6.0%*
Severity: SEVERE
Onset: EARLY
Elevated Hepatic Enzymes Incidence:
4.0-8.0%*
Severity: SEVERE
Onset: DELAYED
Irregular Heart Beat Incidence:
4.5%*
Severity: SEVERE
Onset: EARLY
Skin Rash Incidence:
5.0-8.0%*
Severity: SEVERE
Onset: EARLY
Weight Loss Incidence:
5.0-13.0%*
Severity: MILD
Onset: DELAYED
Bleeding Incidence:
5.0%*
Severity: SEVERE
Onset: EARLY
High Calcium Levels Incidence:
5.0%*
Severity: MODERATE
Onset: DELAYED
Low Blood Sodium Levels Incidence:
5.0%*
Severity: SEVERE
Onset: DELAYED
Blurred Vision Incidence:
6.0%*
Severity: MODERATE
Onset: EARLY
Brain Attack Incidence:
6.0%*
Severity: SEVERE
Onset: EARLY
Inflamed Pancreas Incidence:
6.0%*
Severity: SEVERE
Onset: DELAYED
Cough Incidence:
6.0-18.0%*
Severity: MILD
Onset: DELAYED
Increased Blood Sugar Incidence:
6.0%*
Severity: SEVERE
Onset: DELAYED
Stomach Pain Incidence:
6.0-10.0%*
Severity: SEVERE
Onset: EARLY
High Uric Acid Level Incidence:
7.0%*
Severity: MODERATE
Onset: DELAYED
Fluid Around The Lungs Incidence:
7.0%*
Severity: SEVERE
Onset: DELAYED
Inability To Sleep Incidence:
7.0-12.0%*
Severity: MILD
Onset: EARLY
Heart Failure Incidence:
8.0%*
Severity: SEVERE
Onset: DELAYED
Low Phosphate Level Incidence:
8.0%*
Severity: SEVERE
Onset: DELAYED
Anemia Incidence:
9.0-55.0%*
Severity: SEVERE
Onset: DELAYED
Low Lymphocytes Incidence:
10.0-37.0%*
Severity: SEVERE
Onset: DELAYED
Heart Attack Incidence:
12.0%*
Severity: SEVERE
Onset: DELAYED
Eye Pain Incidence:
13.0%*
Severity: MILD
Onset: EARLY
Eye Irritation Incidence:
13.0%*
Severity: MILD
Onset: RAPID
Dry Eyes Incidence:
13.0%*
Severity: MILD
Onset: EARLY
Low White Blood Cell Counts Incidence:
14.0-63.0%*
Severity: SEVERE
Onset: DELAYED
Low White Blood Cells Incidence:
24.0-63.0%*
Severity: SEVERE
Onset: DELAYED
Low Blood Sugar Incidence:
24.0%*
Severity: MODERATE
Onset: EARLY
Low Platelet Count Incidence:
36.0-57.0%*
Severity: SEVERE
Onset: DELAYED
Pancytopenia Incidence:
48.0%*
Severity: SEVERE
Onset: DELAYED
*This is an approximate aggregated range of reported side effects from clinical studies performed on this drug. Your experience with this drug may be different.
Daily Life Interactions for Iclusig 15mg Tablet

Elements of your daily lifestyle may have an effect on the medications you are taking. Drug interactions can result in unwanted side effects, reduce the effectiveness of your medicine or possibly increase the action of a particular medicine.

Major Lifestyle Interaction
Grapefruit juice and Iclusig 15mg Tablet(Ponatinib)
Grapefruit juice and Ponatinib(Ponatinib)
If you drink grapefruit juice, talk to your health care professional. Taking these drugs together may result in increased levels of ponatinib in your body and increased risk of ponatinib side effects such as fluid retention, bleeding, rash, and/or high blood pressure.
Pregnancy & Lactation Information
FIRST Trimester

Class D - Adequate well-controlled or observational studies in pregnant women have demonstrated a risk to the fetus. However, the benefits of therapy may outweigh the potential risk. For example, the drug may be acceptable if needed in a life-threatening situation or serious disease for which safer drugs cannot be used or are ineffective.

SECOND Trimester

Class D - Adequate well-controlled or observational studies in pregnant women have demonstrated a risk to the fetus. However, the benefits of therapy may outweigh the potential risk. For example, the drug may be acceptable if needed in a life-threatening situation or serious disease for which safer drugs cannot be used or are ineffective.

THIRD Trimester

Class D - Adequate well-controlled or observational studies in pregnant women have demonstrated a risk to the fetus. However, the benefits of therapy may outweigh the potential risk. For example, the drug may be acceptable if needed in a life-threatening situation or serious disease for which safer drugs cannot be used or are ineffective.

Lactation

Avoid - This drug is known to cause harm to infants when taken by nursing mothers.


Learning More About
Visit the Drug Summary page where you can:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics
Learn More
Patient Experiences with Iclusig

Be the first to share your experience!

We want to help our customers stay educated about the medications they are taking. Submit your own observations and experiences to benefit others.

Average Scores
Easy to Take 
0 / 5
0 / 5
Works as Intended 
0 / 5
0 / 5
Tolerable 
0 / 5
0 / 5